Ultragenyx Pharmaceutical Inc (RARE)
46.00
-0.40
(-0.86%)
USD |
NASDAQ |
Nov 21, 16:00
46.00
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Revenue (Quarterly): 139.49M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 139.49M |
| June 30, 2024 | 147.03M |
| March 31, 2024 | 108.83M |
| December 31, 2023 | 127.39M |
| September 30, 2023 | 98.05M |
| June 30, 2023 | 108.31M |
| March 31, 2023 | 100.50M |
| December 31, 2022 | 103.35M |
| September 30, 2022 | 90.70M |
| June 30, 2022 | 89.34M |
| March 31, 2022 | 79.94M |
| December 31, 2021 | 83.39M |
| September 30, 2021 | 81.65M |
| June 30, 2021 | 86.98M |
| March 31, 2021 | 99.40M |
| December 31, 2020 | 91.54M |
| September 30, 2020 | 81.47M |
| Date | Value |
|---|---|
| June 30, 2020 | 61.71M |
| March 31, 2020 | 36.31M |
| December 31, 2019 | 35.59M |
| September 30, 2019 | 25.80M |
| June 30, 2019 | 24.15M |
| March 31, 2019 | 18.17M |
| December 31, 2018 | 16.26M |
| September 30, 2018 | 11.76M |
| June 30, 2018 | 12.79M |
| March 31, 2018 | 10.68M |
| December 31, 2017 | 2.414M |
| September 30, 2017 | 0.198M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.005M |
| September 30, 2016 | 0.111M |
| June 30, 2016 | 0.017M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
35.59M
Minimum
Dec 2019
147.03M
Maximum
Jun 2024
92.55M
Average
91.12M
Median
Revenue (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 500.92M |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -133.52M |
| Total Expenses (Quarterly) | 271.48M |
| EPS Diluted (Quarterly) | -1.40 |
| Enterprise Value | 3.670B |
| Gross Profit Margin (Quarterly) | 84.93% |
| Profit Margin (Quarterly) | -95.71% |
| Earnings Yield | -14.07% |
| Normalized Earnings Yield | -14.12 |